# LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

> **NCT07391566** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 99 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** LPM6690176
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

## Key facts

- **NCT ID:** NCT07391566
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391566, "LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07391566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*